Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by SABBOBCATon Oct 10, 2020 2:40pm
232 Views
Post# 31701190

Earnings and the week ahead

Earnings and the week aheadTH has a habit of waiting until towards the end of the reporting window for earnings. This is frustrating for us investors as we feel behind the curve in what is happening. I think there are a few reasons for the pre release of earnings guidance in September and waiting to the last possible day to fully release on Oct 15th. The pre release was likely an attempt by the finance team to meet the SEC deadline that the company will have to meet once they have been listed for a full year. It is also a good way to set expectations and get the bad news out of the way to clear a path for new messaging. It feels to me like the company was delaying setting am earnings date to give them the opportunity to gather and prepare some data or information. Could it be early Trogarzo numbers out of Europe? or an approval from the FDA on a Nash phase 3? or even some more data from Grinspoon? Who knows, but I feel this week will have a positive tone that dominates the past COVID strained quarter
Bullboard Posts